Deerfield launches radiotherapy company; UCLA gene editing spinout secures funds
Deerfield on Wednesday launched a radiotherapy outfit called Aviko. The new biotech is developing a therapy known as boron neutron capture therapy, or BNCT, which is approved in Japan for head and neck cancers and is also being worked on in Europe.
However, the therapy requires specialized technology and centers, and there are currently none in the US. Deerfield VP of Business Development and Aviko CEO Dave Greenwald said that the biotech’s initial goals are to establish a US BNCT center and to get into the clinic in one to two years.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.